| Formulary Chapter 2: Cardiovascular system - Full Chapter
|
| Chapter Links... |
 Local Process for warfarin to DOAC switch_April 2020 |
| Atrial fibrillation anticoagulant clinical decision aid for use in Primary Care |
| DOAC Counselling Checklist |
| National Guidance: Warfarin to DOAC switching _ April 2020 |
| Warfarin to DOAC switching _ Local Guidance _ April 2020 |
| NICE CG187: Acute heart failure: diagnosis and management |
 UKMI: MI - secondary prevention - Summary of NICE guidance (CG172) |
| Details... |
| 02.05.05.01 |
Angiotensin-converting enzyme inhibitors (ACE inhibitors) |
|
|
Lisinopril
|
First Choice
|
|
|
|
Ramipril
|
First Choice
|
- Primary Care: prescribe as capsules.
|
NICE evidence summary ESUOM45: Ramipril for the symptoms of peripheral arterial disease
|
Enalapril
|
Formulary
|
- NWAFT: Restricted to existing patients and paediatric use.
- Formulary at all other Trusts where 1st line choices are unsuitable.
March 2021: Shortage of enalapril 5mg tablets
Enalapril 5mg tablets will be out of stock in March and April 2021. There is not enough supply of the 2.5mg strength to bridge the gap for all patients. There is stock of 10mg strength available.
For patients stabilised on 5mg dose regimen, this leaves the option of splitting 10mg tablets, which are uncoated and scored. However, the score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses, therefore halving the tablets to deliver a 5mg dose would be unlicensed. Further information to follow
|
|
|
Perindopril erbumine
|
Formulary
|
- Please prescribe generic.
- NWAFT: non formulary
Perindopril arginine is non formulary in all Trust and Primary Care
|
Items which should not routinely be prescribed in primary care: Perindopril Arginine
PrescQIPP: Switching from Coversyl® Arginine products (perindopril arginine) to perindopril erbumine tablets
|
Captopril
|
 Restricted
|
- CUHFT: Accepted on Formulary for use by cardiologists for ACEI test dose; not for treatment. (Hospital only)
- RPH: Restricted to the treatment of refractory autonomic dysreflexia
- NWAFT: formulary
|
|
|
|
|
|
|
|
|
| .... |
| Non Formulary Items |
Captopril and Hydrochlorothiazide (Capozide®)
|
Non Formulary
|
|
MHRA Drug Safety Update: Hydrochlorothiazide- risk of non-melanoma skin cancer, particularly in long-term use
|
Captopril and Hydrochlorothiazide (Co-zidocapt®)
|
Non Formulary
|
|
MHRA Drug Safety Update: Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use
|
Enalapril and Hydrochlorothiazide (Innozide®)
|
Non Formulary
|
|
MHRA Drug Safety Update: Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use
|
Fosinopril
|
Non Formulary
|
|
|
|
Imidapril (Tanatril®)
|
Non Formulary
|
|
|
|
Lisinopril and Hydrochlorothiazide (Carace® Plus)
|
Non Formulary
|
|
MHRA Drug Safety Update: Hydrochlorothiazide - risk of non-melanoma skin cancer, particularly in long-term use
|
Lisinopril and Hydrochlorothiazide (Lisicostad®)
|
Non Formulary
|
|
MHRA Drug Safety Update: Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use
|
Lisinopril and Hydrochlorothiazide (Zestoretic®)
|
Non Formulary
|
|
MHRA Drug Safety Update: Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use
|
Moexipril
|
Non Formulary
|
|
|
|
Perindopril Arginine
|
Non Formulary
|
|
|
|
Quinapril
|
Non Formulary
|
|
|
|
Quinapril and Hydrochlorothiazide
|
Non Formulary
|
|
MHRA Drug Safety Update: Hydrochlorothiazide - risk of non-melanoma skin cancer, particularly in long-term use
|
Ramipril and Felodipine (Triapin®)
|
Non Formulary
|
|
|
|
Trandolapril
|
Non Formulary
|
|
|
|
Trandolapril and Verapamil (Tarka®)
|
Non Formulary
|
|
|
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Available Over the Counter. Consider Self Care |
|
Formulary - Can be prescribed in both secondary and primary care. |
|
Formulary - Specialist Advice, secondary care advice provided for primary care initiation. |
|
Formulary - Specialist initiation without shared care guidance. |
|
Formulary - Specialist initiation with shared care guidance. |
|
Restricted - Prescribing (and monitoring where applicable) to remain with the hospital or specialist service. Not to be prescribed in Primary Care |
|
Not recommended for prescribing. Switch to alternative cost-effective option. |
|
Not recommended for prescribing in primary or secondary care. |
|
Not recommended as no formal application made for addition to the formulary. Contact relevant pharmacy team for further information.
|
|
Non-Formulary (category under review). |
|
|
|
